Form D · Pharmaceuticals
Werewolf Therapeutics, Inc.
Cambridge, MA · CIK 0001785530
Offering snapshot reported Jan 7, 2021 · SEC filing
- Reported sold
- $72.1M Offering amount: $72.1M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 23, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 7, 2021 | Initial | $72,069,999 | No comparison | 19 | SEC filing |
| Aug 13, 2020 | Amendment | $56,172,597 | $24,599,997vs Aug 15, 2019 | 10 | SEC filing |
| Aug 15, 2019 | Initial | $31,572,600 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-385514
Source: Form D, filed Jan 7, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sakae Asanuma | Director |
| Patrick Baeuerle | Director |
| David Cordo | Executive |
| Derek Di Rocco | Director |
| Luke Evnin | Director |
| Daniel Hicklin | Director, Executive |
| Alon Lazarus | Director |
| Briggs Morrison | Director |
| Elise Wang | Director |
| Christoph Westphal | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1030 Massachusetts Avenue Suite 210
Cambridge, MA, 02138
Cambridge, MA, 02138